{"DataElement":{"publicId":"7810095","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Disposal Type","preferredDefinition":"A description of the filgrastim or bioequivalence agent that was disposed.","longName":"7810083v1.0:7801103v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7810083","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Disposal","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act or means of getting rid of something.","longName":"7810079v1.0:5632759v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7810079","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C1474:C37998:C71763:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0117CDB-A5DF-5E9A-E053-4EBD850ABA81","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5632759","version":"1","preferredName":"Disposal","preferredDefinition":"The act or means of getting rid of something.","longName":"C48166","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disposal","conceptCode":"C48166","definition":"The act or means of getting rid of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46D7747E-B3D7-47A3-E053-F662850A8F55","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-24","modifiedBy":"ONEDATA","dateModified":"2017-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0109618-A628-455B-E053-4EBD850A88D4","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"MALUMK","dateModified":"2021-12-20","changeDescription":"Released. 12/20/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7801103","version":"1","preferredName":"Filgrastim Or Bioequivalence Type","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._Something distinguishable as an identifiable class based on common qualities.","longName":"7801103v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Granix","valueDescription":"Tbo-filgrastim","ValueMeaning":{"publicId":"5916940","version":"1","preferredName":"Tbo-filgrastim","longName":"5916940","preferredDefinition":"A biosimilar of filgrastim, a recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Tbo-filgrastim specifically binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tbo-filgrastim","conceptCode":"C137803","definition":"A recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Upon administration, tbo-filgrastim specifically binds to and activates G-CSF receptors, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This stimulates the proliferation of neutrophils and may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN). The pharmacokinetic and pharmacodynamic profile of tbo-filgrastim is bioequivalent to filgrastim.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55C47452-286D-63D9-E053-F662850ACF4B","latestVersionIndicator":"Yes","beginDate":"2017-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0DB062C-81C1-1B55-E053-4EBD850A8699","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-15","modifiedBy":"ONEDATA","dateModified":"2021-11-15","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5D0C5E-3D9F-1638-E053-4EBD850A7241","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"Nivestym","valueDescription":"Filgrastim Biosimilar","ValueMeaning":{"publicId":"7801104","version":"1","preferredName":"Filgrastim Biosimilar","longName":"7801104","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.: A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Biosimilar","conceptCode":"C156644","definition":"A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5D0C5E-3DC0-1638-E053-4EBD850A7241","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5D0C5E-3DD9-1638-E053-4EBD850A7241","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"Zarxio","valueDescription":"Filgrastim-sndz","ValueMeaning":{"publicId":"5916941","version":"1","preferredName":"Filgrastim-sndz","longName":"5916941","preferredDefinition":"A biosimilar of filgrastim, a recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Filgrastim-sndz specifically binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim-sndz","conceptCode":"C137804","definition":"A biosimilar of filgrastim, a recombinant form of the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Filgrastim-sndz specifically binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors. This may decrease the duration and prevent the incidence of chemotherapy-induced neutropenia (CIN).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55C47452-2892-63D9-E053-F662850ACF4B","latestVersionIndicator":"Yes","beginDate":"2017-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5D0C5E-3DED-1638-E053-4EBD850A7241","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"Neupogen","valueDescription":"Filgrastim","ValueMeaning":{"publicId":"3379062","version":"1","preferredName":"Filgrastim","longName":"3379062","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD83-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5D0C5E-3E01-1638-E053-4EBD850A7241","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"Releuko","valueDescription":null,"ValueMeaning":{"publicId":"12413986","version":"1","preferredName":"Releuko","longName":"12413986v1.00","preferredDefinition":"A recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B5907C-E8CA-5A73-E053-731AD00AC70A","latestVersionIndicator":"Yes","beginDate":"2023-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-01-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2B5907C-E8CB-5A73-E053-731AD00AC70A","beginDate":"2023-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-01-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7810084","version":"1","preferredName":"Filgrastim Or Bioequivalence Type","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).:Something distinguishable as an identifiable class based on common qualities.","longName":"C1474:C37998:C71763:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00EEF59-A736-5BF8-E053-4EBD850AA3BF","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5D0C5E-3D89-1638-E053-4EBD850A7241","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"KUMMEROA","dateModified":"2023-01-20","changeDescription":"Released. 12/20/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the brand of filgrastim or similar that was discarded?","type":"Alternate Question Text","description":"What is the brand of filgrastim or similar that was discarded?","url":null,"context":"NHLBI"},{"name":"What is the brand of filgrastim or similar that was discarded?","type":"Application Standard Question Text","description":"What is the brand of filgrastim or similar that was discarded?","url":null,"context":"NHLBI"},{"name":"What was the filgrastim or bi","type":"Preferred Question Text","description":"What was the filgrastim or bioequivalence agent that was disposed?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Alternate Question Text","description":"What was the brand of filgrastim or similar that was discarded?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00B15D1-2512-08B5-E053-4EBD850A412C","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-04-26","changeDescription":"Released. 12/20/2021 KMM","administrativeNotes":"2023.4.26 AQT added per ticket request CADSR0002360. ak","unresolvedIssues":null,"deletedIndicator":"No"}}